Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001326389-25-000109
Filing Date
2025-02-14
Accepted
2025-02-14 16:44:16
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4718
  Complete submission text file 0001326389-25-000109.txt   6613
Mailing Address 16 YORK STREET SUITE 2900 TORONTO A6 M5J 0E6
Business Address 16 YORK STREET SUITE 2900 TORONTO A6 M5J 0E6 416-367-4364
Polar Asset Management Partners Inc. (Filed by) CIK: 0001326389 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 0331
Type: SCHEDULE 13G/A

Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Subject) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92271 | Film No.: 25630145
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)